Genmab's "Capital Increase" Is a $5 Million Rounding Error

There is a press release from Genmab, the Danish antibody company, that reads like small drama: "Capital Increase in Genmab as a Result of Employee Warrant Exercise." New shares being issued, without preemption rights for existing shareholders. Cross a headline like that on a news feed and you might picture a company stepping up to the market to raise money, or existing holders getting quietly watered down.

Then you read the numbers, and the drama is about two decimal places wide. The entire "capital increase" is 24,592 new shares — roughly 0.04% of Genmab's share capital. Employees exercised warrants at various prices and handed the company about 37.9 million Danish kroner, a bit over $5 million. That is not a fundraising. It is a rounding error inside an employee-compensation program. It is worth knowing how to read it, because Genmab files these things a few times a year, and none of them say anything meaningful about the company you actually hold.

The mechanism first. A warrant here is basically a stock option given to an employee: the right to buy a share of Genmab at a set price. When the holder exercises, they pay the company that exercise price in cash and get a freshly created share in return. That single act shows what "capital increase" means in this setting, which is the opposite of the scary version. Cash moves into the company, from the employees, and the only thing that grows on the outside is the share count — by less than half of one-hundredth of one percent.

And "without any preemption rights" is Danish-legal for "there was no rights offering" — no paperwork asking existing shareholders whether they want first crack at the new shares. It sounds like a snub. For a Nasdaq-listed company issuing a token number of shares under a pre-approved compensation plan, it's a formality. What matters is the dilution, and 0.04% does not move the needle for anyone.

Here is the part that actually shows how the machine works. The same compensation program that hands warrants to employees also creates restricted stock units the company has committed to deliver — and to satisfy those commitments Genmab runs the opposite trade at the same time. In February 2026 it launched a buy-back of up to 342,130 shares, worth up to 725 million kroner, explicitly "to honor our commitments under the Restricted Stock Unit program", and completed it for about 615 million kroner. So on one side of the compensation cycle, warrants drip a few thousand new shares into existence; on the other side, the company buys back hundreds of thousands. The warrant exercise is the money-in side. The buy-back is where the share count actually gets managed.

That asymmetry is the tell. A company that needed the $5 million — that was issuing shares to fund operations — would be a very different story. Genmab is not that. It is a cash-generative royalty business: in the first half of 2026 it reported $2.05 billion of revenue, up 25% from a year earlier, on the back of royalties from Darzalex, the blood-cancer drug Johnson & Johnson sells, plus rising sales of its own Epkinly. It raised its full-year guidance in August. A company sitting on that revenue stream does not care about 24,592 new shares one way or the other.

So the honest way to read this headline is as noise at the margin of a compensation program — the kind of thing disclosed because Danish company law requires it, not because anything changed. Watch the buy-back and the quarterly earnings instead. And take a little satisfaction in the inversion: it's called a "capital increase," and the money flowed into the company.